A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Recruiting now · Phase 1
Conditions studied: Platinum-resistant Ovarian Cancer
In brief
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Key facts
- Study ID
- NCT07226427
- Run by
- Stemline Therapeutics, Inc.
- People needed
- 100
- Starts
- 2026-01-10
- Expected to finish
- 2028-06-02
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Highlands Oncology Group — Springdale, Arkansas, United States (enrolling)
- Yale University — New Haven, Connecticut, United States (enrolling)
- Florida Cancer Specialists & Research Institute — Sarasota, Florida, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Mayo Clinic — Rochester, Minnesota, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- Icon Cancer Centre — South Brisbane, Queensland, Australia (enrolling)
- Cancer Research SA — Aberfoyle Park, Australia (enrolling)
- Hospital Universitario Dexeus - Grupo Quironsalud — Barcelona, Spain (enrolling)
- Clínica Universidad Navarra — Madrid, Spain (enrolling)
- Hospital Universitario 12 de Octubre — Madrid, Spain (enrolling)
- Hospital Universitario HM Sanchinarro — Madrid, Spain (enrolling)
- Clínica Universidad de Navarra — Pamplona, Spain (enrolling)
- Hospital Quironsalud Madrid — Pozuelo de Alarcón, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.